Lupus vaccine study: which shot schedule protects best?

NCT ID NCT00611663

Completed Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested two ways to give pneumococcal vaccines to people with lupus, a disease where the immune system attacks the body. One group got a prime-boost strategy (two different vaccines six months apart), while the other got the standard single vaccine. The goal was to see which approach produced a stronger immune response without worsening lupus. The trial involved 47 adults with stable lupus.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pneumococcal vaccines (Prevenar and Pneumo23)
What this could lead to: If successful, this could identify a safer, more effective vaccination schedule for lupus patients to prevent pneumonia.
What could go wrong: This is a small, completed Phase 2/3 trial with only 47 participants, so results may not apply to all lupus patients. The vaccines might not boost immunity enough or could trigger lupus flares.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUPUS ERYTHEMATOSUS, SYSTEMIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUPUS ERYTHEMATOSUS, SYSTEMIC

Contacts and locations

Locations

CIC Vaccinologie - Hopital Cochin

Paris, 75679, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.